A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza

Antiviral Research

Volumn 92, Issue 1, 2011, Pages 15-26

  Mancini, Nicasio ^a   Solforosi, Laura ^a   Clementi, Nicola ^a   De Marco, Donata ^a   Clementi, Massimo ^a   Burioni, Roberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Influenza viruses; Monoclonal antibodies; Universal epitopes

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14C2; MONOCLONAL ANTIBODY 1B12; MONOCLONAL ANTIBODY 1E11; MONOCLONAL ANTIBODY 4C11; MONOCLONAL ANTIBODY 5B2; MONOCLONAL ANTIBODY 8C6; MONOCLONAL ANTIBODY 8H12; MONOCLONAL ANTIBODY A06; MONOCLONAL ANTIBODY C179; MONOCLONAL ANTIBODY CR6261; MONOCLONAL ANTIBODY F10; MONOCLONAL ANTIBODY FC41; MONOCLONAL ANTIBODY HCA 2; MONOCLONAL ANTIBODY HCA 3; MONOCLONAL ANTIBODY L18; MONOCLONAL ANTIBODY MEM5; MONOCLONAL ANTIBODY NC10; MONOCLONAL ANTIBODY NC41; MONOCLONAL ANTIBODY O19; MONOCLONAL ANTIBODY P6; MONOCLONAL ANTIBODY PN SIA 28; MONOCLONAL ANTIBODY PN SIA 49; MONOCLONAL ANTIBODY S1; MONOCLONAL ANTIBODY Z3G1; PROTEIN M2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS SIALIDASE;

ARTICLE; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VIRAL PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 80052849858     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.07.013     Document Type: Article

References (183)

1. Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 2006, 11:971-976.
2. Ansaldi F., Canepa P., Parodi V., Bacilieri S., Orsi A., Compagnino F., Icardi G., Durando P. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009, 27:3345-3348.
3. Assarsson E., Bui H.H., Sidney J., Zhang Q., Glenn J., Oseroff C., Mbawuike I.N., Alexander J., Newman M.J., Grey H., Sette A. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J. Virol. 2008, 82:12241-12251.
4. Baudin F., Bach C., Cusack S., Ruigrok R.W. Structure of influenza virus RNP. I. Influenza virus nucleoprotein melts secondary structure in panhandle RNA and exposes the bases to the solvent. EMBO J. 1994, 13:3158-3165.
5. Beerli R.R., Bauer M., Buser R.B., Gwerder M., Muntwiler S., Maurer P., Saudan P., Bachmann M.F. Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl. Acad. Sci. USA 2008, 105:14336-14341.
6. Beerli R.R., Bauer M., Schmitz N., Buser R.B., Gwerder M., Muntwiler S., Renner W.A., Saudan P., Bachmann M.F. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J. 2009, 6:224.
7. Beigel J., Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008, 78:91-102.
8. Besselaar T.G., Naidoo D., Buys A., Gregory V., McAnerney J., Manamela J.M., Blumberg L., Schoub B.D. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 2008, 14:1809-1810.
9. Brett I.C., Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005, 339:273-280.
10. Brezinschek H.P., Brezinschek R.I., Lipsky P.E. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J. Immunol. 1995, 155:190-202.
11. Bui M., Wills E.G., Helenius A., Whittaker G.R. Role of the influenza virus M1 protein in nuclear export of viral ribonucleoproteins. J. Virol. 2000, 74:1781-1786.
12. Burch J., Corbett M., Stock C., Nicholson K., Elliot A.J., Duffy S., Westwood M., Palmer S., Stewart L. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect. Dis. 2009, 9:537-545.
13. Burch J., Paulden M., Conti S., Stock C., Corbett M., Welton N.J., Ades A.E., Sutton A., Cooper N., Elliot A.J., Nicholson K., Duffy S., McKenna C., Stewart L., Westwood M., Palmer S. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol. Assess. 2009, 13:1-265. (iii-iv).
14. Burioni R., Canducci F., Clementi M. Pregnancy and H1N1 infection. Lancet 2009, 374:1417. (author reply 1417-1418).
15. Burioni R., Canducci F., Mancini N., Clementi N., Sassi M., De Marco D., Saita D., Diotti R.A., Sautto G., Sampaolo M., Clementi M. Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol. 2009, 32:319-324.
16. Burioni R., Canducci F., Mancini N., Clementi N., Sassi M., De Marco D., Diotti R.A., Saita D., Sampaolo M., Sautto G., Pianezze M., Clementi M. Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology 2010, 399:144-152.
17. Burton D.R., Parren P.W. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?. Nat. Med. 2000, 6:123-125.
18. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 2008, 181:4168-4176.
19. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
20. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31:417-427.
21. Chandra P.K., Hazari S., Poat B., Gunduz F., Prabhu R., Liu G., Burioni R., Clementi M., Garry R.F., Dash S. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol. J. 2010, 7:118-129.
22. Cheng P.K., Leung T.W., Ho E.C., Leung P.C., Ng A.Y., Lai M.Y., Lim W.W. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg. Infect. Dis. 2009, 15:966-968.
23. Chizhmakov I.V., Geraghty F.M., Ogden D.C., Hayhurst A., Antoniou M., Hay A.J. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J. Physiol. 1996, 494:329-336.
24. Chizhmakov I.V., Ogden D.C., Geraghty F.M., Hayhurst A., Skinner A., Betakova T., Hay A.J. Differences in conductance of M2 proton channels of two influenza viruses at low and high pH. J. Physiol. 2003, 546:427-438.
25. Chutinimitkul S., Herfst S., Steel J., Lowen A.C., Ye J., van Riel D., Schrauwen E.J., Bestebroer T.M., Koel B., Burke D.F., Sutherland-Cash K.H., Whittleston C.S., Russell C.A., Wales D.J., Smith D.J., Jonges M., Meijer A., Koopmans M., Rimmelzwaan G.F., Kuiken T., Osterhaus A.D., Garcia-Sastre A., Perez D.R., Fouchier R.A. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J. Virol. 2010, 84:11802-11813.
26. Clementi M. Perspectives and opportunities for novel antiviral treatments targeting virus fitness. Clin. Microbiol. Infect. 2008, 14:629-631.
27. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 1986, 24:157-160.
28. Colman P.M., Laver W.G., Varghese J.N., Baker A.T., Tulloch P.A., Air G.M., Webster R.G. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 1987, 326:358-363.
29. Colman P.M., Tulip W.R., Varghese J.N., Tulloch P.A., Baker A.T., Laver W.G., Air G.M., Webster R.G. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1989, 323:511-518.
30. Corti D., Suguitan A.L., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F., Santos C., Luke C.J., Torres-Velez F.J., Temperton N.J., Weiss R.A., Sallusto F., Subbarao K., Lanzavecchia A. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010, 120:1663-1673.
31. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Lowenadler B., Lycke N., Jou W.M., Saelens X. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.
32. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353:2667-2672.
33. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., Abed Y., Savard C., Pare C., Lopez Macias C., Boivin G., Leclerc D. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26:3395-3403.
34. Derossi D., Joliot A.H., Chassaing G., Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 269:10444-10450.
35. Dormitzer P.R., Galli G., Castellino F., Golding H., Khurana S., Del Giudice G., Rappuoli R. Influenza vaccine immunology. Immunol. Rev. 2011, 239:167-177.
36. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
37. Epstein S.L., Price G.E. Cross-protective immunity to influenza A viruses. Expert Rev. Vaccines 2010, 9:1325-1341.
38. Epstein S.L., Misplon J.A., Lawson C.M., Subbarao E.K., Connors M., Murphy B.R. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J. Immunol. 1993, 150:5484-5493.
39. Epstein S.L., Lo C.Y., Misplon J.A., Lawson C.M., Hendrickson B.A., Max E.E., Subbarao K. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J. Immunol. 1997, 158:1222-1230.
40. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D., Tai W., Cramer D.V., Adler-Moore J.P., Fujii G. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
41. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., Fu T.M., Joyce J., Przysiecki C.T., Keller P.M., Garsky V.M., Ionescu R., Rippeon Y., Shi L., Chastain M.A., Condra J.H., Davies M.E., Liao J., Emini E.A., Shiver J.W. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
42. Feng J., Zhang M., Mozdzanowska K., Zharikova D., Hoff H., Wunner W., Couch R.B., Gerhard W. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 2006, 3:102.
43. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A " universal" human influenza A vaccine. Virus Res. 2004, 103:173-176.
44. Fiore A.E., Fry A., Shay D., Gubareva L., Bresee J.S., Uyeki T.M. Antiviral agents for the treatment and chemoprophylaxis of influenza-- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill. Summ. 2011, 60:1-24.
45. Fleming D.M., Andrews N.J., Ellis J.S., Bermingham A., Sebastianpillai P., Elliot A.J., Miller E., Zambon M. Estimating influenza vaccine effectiveness using routinely collected laboratory data. J. Epidemiol. Commun. Health 2010, 64:1062-1067.
46. Fodor E., Crow M., Mingay L.J., Deng T., Sharps J., Fechter P., Brownlee G.G. A single amino acid mutation in the PA subunit of the influenza virus RNA polymerase inhibits endonucleolytic cleavage of capped RNAs. J. Virol. 2002, 76:8989-9001.
47. Fouchier R.A., Munster V., Wallensten A., Bestebroer T.M., Herfst S., Smith D., Rimmelzwaan G.F., Olsen B., Osterhaus A.D. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 2005, 79:2814-2822.
48. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 17:2237-2244.
49. Friesen R.H., Koudstaal W., Koldijk M.H., Weverling G.J., Brakenhoff J.P., Lenting P.J., Stittelaar K.J., Osterhaus A.D., Kompier R., Goudsmit J. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010, 5:e9106.
50. Fu T.M., Freed D.C., Horton M.S., Fan J., Citron M.P., Joyce J.G., Garsky V.M., Casimiro D.R., Zhao Q., Shiver J.W., Liang X. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 2009, 385:218-226.
51. Gamblin S.J., Skehel J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J. Biol. Chem. 2010, 285:28403-28409.
52. Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol. Rev. 1997, 159:95-103.
53. Gerhard W., Mozdzanowska K., Zharikova D. Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 2006, 12:569-574.
54. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010, 28:4895-4902.
55. Gravel C., Li C., Wang J., Hashem A.M., Jaentschke B., Xu K.W., Lorbetskie B., Gingras G., Aubin Y., Van Domselaar G., Girard M., He R., Li X. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 2010, 28:5774-5784.
56. Gulati U., Hwang C.C., Venkatramani L., Gulati S., Stray S.J., Lee J.T., Laver W.G., Bochkarev A., Zlotnick A., Air G.M. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J. Virol. 2002, 76:12274-12280.
57. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
58. Hensley S.E., Das S.R., Bailey A.L., Schmidt L.M., Hickman H.D., Jayaraman A., Viswanathan K., Raman R., Sasisekharan R., Bennink J.R., Yewdell J.W. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009, 326:734-736.
59. Ho H.T., Qian H.L., He F., Meng T., Szyporta M., Prabhu N., Prabakaran M., Chan K.P., Kwang J. Rapid detection of H5N1 subtype influenza viruses by antigen capture enzyme-linked immunosorbent assay using H5- and N1-specific monoclonal antibodies. Clin. Vaccine Immunol. 2009, 16:726-732.
60. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166:7381-7388.
61. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., Makarova N., Perez D.R., Macdonald G.H., McCullers J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006, 13:981-990.
62. Hui E.K., Yap E.M., An D.S., Chen I.S., Nayak D.P. Inhibition of influenza virus matrix (M1) protein expression and virus replication by U6 promoter-driven and lentivirus-mediated delivery of siRNA. J. Gen. Virol. 2004, 85:1877-1884.
63. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., Tang J., McDonald W., Song L., Evans R.K., Umlauf S., Tussey L., Powell T.J. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
64. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 1991, 65:5491-5498.
65. Iwatsuki-Horimoto K., Horimoto T., Noda T., Kiso M., Maeda J., Watanabe S., Muramoto Y., Fujii K., Kawaoka Y. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J. Virol. 2006, 80:5233-5240.
66. Jackson D.C., Webster R.G. A topographic map of the enzyme active center and antigenic sites on the neuraminidase of influenza virus A/Tokyo/3/67 (H2N2). Virology 1982, 123:69-77.
67. Jameson J., Cruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998, 72:8682-8689.
68. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172:5598-5605.
69. Johansson B.E., Matthews J.T., Kilbourne E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998, 16:1009-1015.
70. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 2008, 6:143-155.
71. Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., Perry K.J., Faynboym A., Ilhan M., Horowitz M., Horowitz L., Palese P., Bhatt R.R., Lerner R.A. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. USA 2008, 105:5986-5991.
72. Kashyap A.K., Steel J., Rubrum A., Estelles A., Briante R., Ilyushina N.A., Xu L., Swale R.E., Faynboym A.M., Foreman P.K., Horowitz M., Horowitz L., Webby R., Palese P., Lerner R.A., Bhatt R.R. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog. 2010, 6:e1000990.
73. Kaverin N.V., Rudneva I.A., Ilyushina N.A., Varich N.L., Lipatov A.S., Smirnov Y.A., Govorkova E.A., Gitelman A.K., Lvov D.K., Webster R.G. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 2002, 83:2497-2505.
74. Kaverin N.V., Rudneva I.A., Ilyushina N.A., Lipatov A.S., Krauss S., Webster R.G. Structural differences among hemagglutinins of influenza A virus subtypes are reflected in their antigenic architecture: analysis of H9 escape mutants. J. Virol. 2004, 78:240-249.
75. Kaverin N.V., Rudneva I.A., Govorkova E.A., Timofeeva T.A., Shilov A.A., Kochergin-Nikitsky K.S., Krylov P.S., Webster R.G. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J. Virol. 2007, 81:12911-12917.
76. Kawaoka Y., Yamnikova S., Chambers T.M., Lvov D.K., Webster R.G. Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus. Virology 1990, 179:759-767.
77. Kitching A., Roche A., Balasegaram S., Heathcock R., Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Eur. Surveill. 2009, 14:19287.
78. Koudstaal W., Koldijk M.H., Brakenhoff J.P., Cornelissen L.A., Weverling G.J., Friesen R.H., Goudsmit J. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice. viable alternative to oseltamivir. J. Infect. Dis. 2009, 200:1870-1873.
79. Krause J.C., Tumpey T.M., Huffman C.J., McGraw P.A., Pearce M.B., Tsibane T., Hai R., Basler C.F., Crowe J.E. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J. Virol. 2010, 84:3127-3130.
80. Kreijtz J.H., Bodewes R., van Amerongen G., Kuiken T., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007, 25:612-620.
81. Kreijtz J.H., de Mutsert G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J. Virol. 2008, 82:5161-5166.
82. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., Smith L.R. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 2008, 197:1643-1652.
83. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
84. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N. Engl. J. Med. 2010, 363:2036-2044.
85. Lee J.T., Air G.M. Interaction between a 1998 human influenza virus N2 neuraminidase and monoclonal antibody Mem5. Virology 2006, 345:424-433.
86. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., Peng Y.C., McMichael A.J., Farrar J.J., Smith G.L., Townsend A.R., Askonas B.A., Rowland-Jones S., Dong T. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Invest. 2008, 118:3478-3490.
87. Leopold P.L., Wendland R.L., Vincent T., Crystal R.G. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J. Virol. 2006, 80:10237-10247.
88. Liang S., Mozdzanowska K., Palladino G., Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 1994, 152:1653-1661.
89. Lim A.P., Wong S.K., Chan A.H., Chan C.E., Ooi E.E., Hanson B.J. Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virol. J. 2008, 5:80.
90. Liu W., Li H., Chen Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol. 2003, 35:141-146.
91. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23:366-371.
92. Liu W., Zou P., Chen Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol. Lett. 2004, 93:131-136.
93. Luke T.C., Kilbane E.M., Jackson J.L., Hoffman S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann. Intern. Med. 2006, 145:599-609.
94. Malby R.L., Tulip W.R., Harley V.R., McKimm-Breschkin J.L., Laver W.G., Webster R.G., Colman P.M. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 1994, 2:733-746.
95. Mancini, N., Solforosi, L., De Marco, D., and Clementi, N. (2010). Heterosubtypic neutralizing activity of two human monoclonal antibodies recognizing epitopes broadly shared among different influenza subtypes. Antiviral Congress, Amsterdam, The Netherlands, 7-9 November 2010. Abstract P2.54.
96. Manheimer-Lory A., Katz J.B., Pillinger M., Ghossein C., Smith A., Diamond B. Molecular characteristics of antibodies bearing an anti-DNA-associated idiotype. J. Exp. Med. 1991, 174:1639-1652.
97. McCauley J.W., Mahy B.W. Structure and function of the influenza virus genome. Biochem. J. 1983, 211:281-294.
98. McCown M.F., Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J. Virol. 2006, 80:8178-8189.
99. McDonald N.J., Smith C.B., Cox N.J. Antigenic drift in the evolution of H1N1 influenza A viruses resulting from deletion of a single amino acid in the haemagglutinin gene. J. Gen. Virol. 2007, 88:3209-3213.
100. Monto A.S., Kendal A.P. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973, 1:623-625.
101. Monto A.S., Ansaldi F., Aspinall R., McElhaney J.E., Montano L.F., Nichol K.L., Puig-Barbera J., Schmitt J., Stephenson I. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 2009, 27:5043-5053.
102. Moreno A., Brocchi E., Lelli D., Gamba D., Tranquillo M., Cordioli P. Monoclonal antibody based ELISA tests to detect antibodies against neuraminidase subtypes 1, 2 and 3 of avian influenza viruses in avian sera. Vaccine 2009, 27:4967-4974.
103. Mould J.A., Drury J.E., Frings S.M., Kaupp U.B., Pekosz A., Lamb R.A., Pinto L.H. Permeation and activation of the M2 ion channel of influenza A virus. J. Biol. Chem. 2000, 275:31038-31050.
104. Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254:138-146.
105. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., Gerhard W. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
106. Muckelbauer J.K., Rossmann M.G. The structure of coxsackievirus B3. Curr. Top. Microbiol. Immunol. 1997, 223:191-208.
107. Muckelbauer J.K., Kremer M., Minor I., Tong L., Zlotnick A., Johnson J.E., Rossmann M.G. Structure determination of coxsackievirus B3 to 3.5 A resolution. Acta Crystallogr. D Biol. Crystallogr 1995, 51:871-887.
108. Mukhtar M.M., Li S., Li W., Wan T., Mu Y., Wei W., Kang L., Rasool S.T., Xiao Y., Zhu Y., Wu J. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Int. J. Biochem. Cell. Biol. 2009, 41:554-560.
109. Nabel G.J., Fauci A.S. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 2010, 16:1389-1391.
110. Naikhin A.N., Tsaritsina I.M., Oleinikova E.V., Syrodoeva L.G., Korchanova N.L., Denisov G.M., Ya Shvartsman S. The importance of antineuraminidase antibodies in resistance to influenza A and immunologic memory for their synthesis. J. Hyg. (Lond.) 1983, 91:131-138.
111. Nayak D.P., Hui E.K., Barman S. Assembly and budding of influenza virus. Virus Res. 2004, 106:147-165.
112. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5:1157-1163.
113. Nguyen H.H., van Ginkel F.W., Vu H.L., McGhee J.R., Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J. Infect. Dis. 2001, 183:368-376.
114. Noda T., Sagara H., Yen A., Takada A., Kida H., Cheng R.H., Kawaoka Y. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 2006, 439:490-492.
115. Okada J., Ohshima N., Kubota-Koketsu R., Ota S., Takase W., Azuma M., Iba Y., Nakagawa N., Yoshikawa T., Nakajima Y., Ishikawa T., Asano Y., Okuno Y., Kurosawa Y. Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003. Virology 2010, 397:322-330.
116. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67:2552-2558.
117. Okuno Y., Matsumoto K., Isegawa Y., Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 1994, 68:517-520.
118. Palese, P. (2004). Influenza: old and new threats. Nat. Med. 10 (Suppl.), S82-S87.
119. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 1995, 69:2075-2081.
120. Palmer P., Charley B., Rombaut B., Daeron M., Lebon P. Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32). Virology 2000, 278:86-94.
121. Perotti M., Ghidoli N., Altara R., Diotti R.A., Clementi N., De Marco D., Sassi M., Clementi M., Burioni R., Mancini N. Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun. Rev. 2008, 7:468-472.
122. Ping J., Li C., Deng G., Jiang Y., Tian G., Zhang S., Bu Z., Chen H. Single-amino-acid mutation in the HA alters the recognition of H9N2 influenza virus by a monoclonal antibody. Biochem. Biophys. Res. Commun. 2008, 371:168-171.
123. Pinto L.H., Holsinger L.J., Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69:517-528.
124. Pos W., Luken B.M., Hovinga J.A., Turenhout E.A., Scheiflinger F., Dong J.F., Fijnheer R., Voorberg J. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 2009, 7:421-428.
125. Poungpair O., Chaicumpa W., Kulkeaw K., Maneewatch S., Thueng-in K., Srimanote P., Tongtawe P., Songserm T., Lekcharoensuk P., Tapchaisri P. Human single chain monoclonal antibody that recognizes matrix protein of heterologous influenza A virus subtypes. J. Virol. Methods 2009, 159:105-111.
126. Poungpair O., Pootong A., Maneewatch S., Srimanote P., Tongtawe P., Songserm T., Tapchaisri P., Chaicumpa W. A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus. Bioconjug. Chem. 2010, 21:1134-1141.
127. Prabhu R., Khalap N., Burioni R., Clementi M., Garry R.F., Dash S. Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. Am. J. Pathol. 2004, 165:1163-1173.
128. Quan F.S., Compans R.W., Nguyen H.H., Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 2008, 82:1350-1359.
129. Quan F.S., Steinhauer D., Huang C., Ross T.M., Compans R.W., Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 2008, 26:3352-3361.
130. Ramirez-Gonzalez J.E., Gonzalez-Duran E., Alcantara-Perez P., Wong-Arambula C., Olivera-Diaz H., Cortez-Ortiz I., Barrera-Badillo G., Nguyen H., Gubareva L., Lopez-Martinez I., Diaz-Quinonez J.A., Lezana-Fernandez M.A., Gatell-Ramirez H.L., Cordova Villalobos J.A., Hernandez-Avila M., Alpuche-Aranda C. Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Mexico. Emerg. Infect. Dis. 2011, 17:283-286.
131. Renegar K.B., Small P.A., Boykins L.G., Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 2004, 173:1978-1986.
132. Sakabe S., Iwatsuki-Horimoto K., Horimoto T., Nidom C.A., Le M.Q., Takano R., Kubota-Koketsu R., Okuno Y., Ozawa M., Kawaoka Y.A. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res. 2009, 88:249-255.
133. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., Arpino R., Tamane A., Kandil A., James O., Underdown B., Klein M., Katz J., Burt D. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 2001, 211:143-153.
134. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., Butler E.N., Wallis T.R., Klimov A.I., Gubareva L.V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 2008, 52:3284-3292.
135. Simmons C.P., Bernasconi N.L., Suguitan A.L., Mills K., Ward J.M., Chau N.V., Hien T.T., Sallusto F., Hado Q., Farrar J., de Jong M.D., Lanzavecchia A., Subbarao K. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007, 4:e178.
136. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
137. Skehel J.J., Stevens D.J., Daniels R.S., Douglas A.R., Knossow M., Wilson I.A., Wiley D.C. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 1984, 81:1779-1783.
138. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-1402.
139. Smirnov Y.A., Lipatov A.S., Gitelman A.K., Okuno Y., Van Beek R., Osterhaus A.D., Claas E.C. An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol. 1999, 43:237-244.
140. Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol. J. 2010, 7:351.
141. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., Garcia-Sastre A., Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1(1).
142. Steinhoff M.C. Influenza in young children: burden, immunisation, and policy. Lancet Infect. Dis. 2011, 11:2-3.
143. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
144. Sukeno N., Otsuki Y., Konno J., Yamane N., Odagiri T., Arikawa J., Ishida N. Anti-nucleoprotein antibody response in influenza A infection. Tohoku J. Exp. Med. 1979, 128:241-249.
145. Sultana I., Gao J., Markoff L., Eichelberger M.C. Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine 2011, 29:2601-2606.
146. Sylte M.J., Suarez D.L. Influenza neuraminidase as a vaccine antigen. Curr. Top. Microbiol. Immunol. 2009, 333:227-241.
147. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003, 21:3212-3218.
148. Tamura S. Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 2010, 28:6393-6397.
149. Tan P.T., Heiny A.T., Miotto O., Salmon J., Marques E.T., Lemonnier F., August J.T. Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One 2010, 5:e8754.
150. Thathaisong U., Maneewatch S., Kulkeaw K., Thueng-In K., Poungpair O., Srimanote P., Songserm T., Tongtawe P., Tapchaisri P., Chaicumpa W. Human monoclonal single chain antibodies (HuScFv) that bind to the polymerase proteins of influenza A virus. Asian Pac. J. Allergy Immunol. 2008, 26:23-35.
151. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., Cinatl J., ter Meulen J., Lasters I., Carsetti R., Peiris M., de Kruif J., Goudsmit J. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008, 3:e3942.
152. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., Epstein S.L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007, 13:426-435.
153. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 1990, 64:1375-1377.
154. Tsuchiya E., Sugawara K., Hongo S., Matsuzaki Y., Muraki Y., Li Z.N., Nakamura K. Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. J. Gen. Virol. 2001, 82:2475-2484.
155. Tu W., Mao H., Zheng J., Liu Y., Chiu S.S., Qin G., Chan P.L., Lam K.T., Guan J., Zhang L., Guan Y., Yuen K.Y., Peiris J.S., Lau Y.L. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J. Virol. 2010, 84:6527-6535.
156. Tulip W.R., Varghese J.N., Laver W.G., Webster R.G., Colman P.M. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 1992, 227:122-148.
157. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 2001, 75:5141-5150.
158. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.R., Martinez D., Perry H.C., Shiver J.W., Montgomery D.L., Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
159. Underwood P.A. Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies. J. Gen. Virol. 1982, 62:153-169.
160. VanEs J.H., Aanstoot H., Gmelig-Meyling F.H., Derksen R.H., Logtenberg T. A human systemic lupus erythematosus-related anti-cardiolipin/single-stranded DNA autoantibody is encoded by a somatically mutated variant of the developmentally restricted 51P1 VH gene. J. Immunol. 1992, 149:2234-2240.
161. Vareckova E., Mucha V., Wharton S.A., Kostolansky F. Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch. Virol. 2003, 148:469-486.
162. Verkoczy L., Diaz M., Holl T.M., Ouyang Y.B., Bouton-Verville H., Alam S.M., Liao H.X., Kelsoe G., Haynes B.F. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc. Natl. Acad. Sci. USA 2010, 107:181-186.
163. Wang T.T., Palese P. Universal epitopes of influenza virus hemagglutinins?. Nat. Struct. Mol. Biol. 2009, 16:233-234.
164. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., Koriazova L., Madura L., Shapiro L., Matsumoto A., Yoshida H., Mikayama T., Kubo R.T., Sarawar S., Cheroutre H., Kato S. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res. 2008, 80:168-177.
165. Wang C.C., Chen J.R., Tseng Y.C., Hsu C.H., Hung Y.F., Chen S.W., Chen C.M., Khoo K.H., Cheng T.J., Cheng Y.S., Jan J.T., Wu C.Y., Ma C., Wong C.H. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl. Acad. Sci. USA 2009, 106:18137-18142.
166. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., Ratnamohan M., McPhie K., Cunningham A.L., Saksena N.K. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res. 2010, 87:16-21.
167. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010, 6:e1000796.
168. Webster R.G., Brown L.E., Laver W.G. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 1984, 135:30-42.
169. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992, 56:152-179.
170. Whittaker G., Bui M., Helenius A. The role of nuclear import and export in influenza virus infection. Trends Cell. Biol. 1996, 6:67-71.
171. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289:373-378.
172. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289:366-373.
173. Wrammert J., Koutsonanos D., Li G.M., Edupuganti S., Sui J., Morrissey M., McCausland M., Skountzou I., Hornig M., Lipkin W.I., Mehta A., Razavi B., Del Rio C., Zheng N.Y., Lee J.H., Huang M., Ali Z., Kaur K., Andrews S., Amara R.R., Wang Y., Das S.R., O'Donnell C.D., Yewdell J.W., Subbarao K., Marasco W.A., Mulligan M.J., Compans R., Ahmed R., Wilson P.C. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208:181-193.
174. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25:8868-8873.
175. Yang J., Yoshida R., Kariya Y., Zhang X., Hashiguchi S., Nakashima T., Suda Y., Takada A., Ito Y., Sugimura K. Characterization of human single-chain antibodies against highly pathogenic avian influenza H5N1 viruses: mimotope and neutralizing activity. J. Biochem. 2010, 148:507-515.
176. Yewdell J.W., Frank E., Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J. Immunol. 1981, 126:1814-1819.
177. Yu X., Tsibane T., McGraw P.A., House F.S., Keefer C.J., Hicar M.D., Tumpey T.M., Pappas C., Perrone L.A., Martinez O., Stevens J., Wilson I.A., Aguilar P.V., Altschuler E.L., Basler C.F., Crowe J.E. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455:532-536.
178. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 1988, 62:2762-2772.
179. Zebedee S.L., Richardson C.D., Lamb R.A. Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol. 1985, 56:502-511.
180. Zharikova D., Mozdzanowska K., Feng J., Zhang M., Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J. Virol. 2005, 79:6644-6654.
181. Zheng B., Zhang Y., He H., Marinova E., Switzer K., Wansley D., Mbawuike I., Han S. Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. J. Immunol. 2007, 179:6153-6159.
182. Zhou B., Zhong N., Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 2007, 357:1450-1451.
183. Zou P., Liu W., Chen Y.H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int. Immunopharmacol. 2005, 5:631-635.